Session » (1513–1533) Systemic Sclerosis & Related Disorders – Clinical Poster II: Clinical Trial, Treatment & Intervention

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 1531

A Retrospective Analysis of the Efficacy of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD): A TriNetX Database Study

9:00AM-11:00AM: Abstract Number: 1527

Acute Effects of Intravenous Iloprost on Finger Power Doppler Ultrasound in Scleroderma Patients

9:00AM-11:00AM: Abstract Number: 1525

Chelation Therapy in the Management of Calcinosis Associated with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1517

Comparing Deep Neural Network to Modified Rodnan Skin Score in a Trial for Belumosudil in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 1518

Efficacy and Safety of Prostaglandins Analogues in Systemic Sclerosis-associated Raynaud’s Phenomenon. a Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1526

Evusheld Efficacy and Safety in Autoimmune Rheumatic Diseases (AIRD) Treated by B Cell Depeting Therapy or Autologous Stem Cell Transplantation: A Prospective Observational Study

9:00AM-11:00AM: Abstract Number: 1520

Identifying Core Domains for Clinical Trials in Systemic Sclerosis-Associated Raynaud’s Phenomenon and Digital Ulcers Using the Delphi Consensus Method

9:00AM-11:00AM: Abstract Number: 1528

Intravenous or Subcutaneous Immunoglobulins as Potential Treatment for Gastrointestinal, Cutaneous and Vascular Involvement in Systemic Sclerosis: Data from an Italian Cohort of 65 Patients

9:00AM-11:00AM: Abstract Number: 1533

Long-term Use of Rituximab in Systemic Sclerosis: A Real-life Italian Multicentre Study

9:00AM-11:00AM: Abstract Number: 1521

Microvascular Remodeling After Autologous Stem Cell Transplant for Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1529

Mycophenolate Mofetil Use in Clinical Practice: Persistence on Therapy and Long-term Adverse Events in a Multicentric Cohort of Scleroderma Patients

9:00AM-11:00AM: Abstract Number: 1530

Outcomes in Patients with Systemic Sclerosis Following Lung Transplantation: An Italian Multicentre Experience

9:00AM-11:00AM: Abstract Number: 1515

Performance of the Revised CRISS in a Phase 3 Trial of Early Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1514

Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients with Connective Tissue Disorders

9:00AM-11:00AM: Abstract Number: 1519

Renal Complications Following Autologous Stem Cell Transplantation for Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1532

Safety and Microvascular Effects of Long-term Treatment with Aminaphtone in Systemic Sclerosis Patients: A Retrospective Analysis

9:00AM-11:00AM: Abstract Number: 1516

Systemic Sclerosis Gastrointestinal Tract Vascular Biomarkers of Symptomatic Disease Activity

9:00AM-11:00AM: Abstract Number: 1524

The Effectiveness of Nintedanib in Treating Fibrosing Interstitial Lung Disease in Both Scleroderma and Non-scleroderma Patients: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1523

The Risk of Scleroderma Renal Crisis from Intraarticular Corticosteroid Injection in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1522

Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis

9:00AM-11:00AM: Abstract Number: 1513

Trends in Systemic Sclerosis- related Mortality by Age, Sex and Race in the United States, 1999-2019

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].